Key result
In an experimental dog model of venous thrombosis, ancrod therapy following streptokinase thrombolysis maintained vein patency in 36% of veins at 6 days, compared to 0% with no further treatment.
Why the study?
Does streptokinase followed by ancrod prevent rethrombosis compared to streptokinase alone in an experimental dog model of venous thrombosis?
Does streptokinase followed by ancrod prevent rethrombosis compared to streptokinase alone in an experimental dog model of venous thrombosis?
In a canine model of venous thrombosis, sequential therapy with streptokinase and ancrod showed potential to maintain vein patency better than streptokinase alone, though efficacy was limited by incomplete initial thrombolysis and bleeding.
Answers are grounded in this paper and cite their sources.
No immediate clinical role for ancrod post-streptokinase; leaves open translation to human venous thrombosis trials.
Phenol was applied to the exposed femoral veins of anaesthetized dogs and the fate of the induced thrombi was followed by serial phlebography and eventual histology. Thrombi less than 24 hours old were treated with a 9-hour infusion of streptokinase and patency was restored in 38 of 48 veins (79 percent). Rethrombosis had occurred 6 days later in all of 10 veins which received no further treatment. Five of 14 veins (36 per cent) remained patent when dogs were given treatment with ancrod following thrombolysis by streptokinase. Probable explanations for rethrombosis in the other 9 veins despite ancrod therapy were failure to clear the veins completely of thrombi with streptokinase and failure to maintain a sufficiently low level of plasma fibrinogen in some dogs because of bleeding. Streptokinase therapy followed by ancrod warrants further study in the treatment of deep-vein thrombosis.
No takes yet. Share an insight, caveat, or question.
Pitney et al. (1971) studied Experimental venous thrombosis. Streptokinase followed by ancrod vs. Streptokinase followed by no further treatment was evaluated on Vein patency at 6 days. In an experimental dog model of venous thrombosis, ancrod therapy following streptokinase thrombolysis maintained vein patency in 36% of veins at 6 days, compared to 0% with no further treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: